Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Cetuximab in Recurrent Resectable HNSCC
NCT05586100Phase 2Active, not recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Oct 2022
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Shanghai Ninth People's Hospital. Started Oct 2022; status: active, not recruiting.
02
Drugs
toripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05586100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05586100.